Enhance the clinical evaluation of AML MRD by uncovering clonality

Minimal Residual Disease (MRD) detection and monitoring hold great promise to be used in clinical trials and beyond patient therapy selection. If single nucleotide variants (SNVs) are detected early on, then better patient stratification and treatment options may be employed to try and prevent relapse. Dr. Asiri Ediriwickrema, from Ravindra Majeti lab at Stanford University, showcases his recent publication in the journal Blood Advances, where they consider how single-cell DNA sequencing enhances MRD detection.

RESEARCHER spotlight

Customer Spotlight: Servier Pharmaceuticals

RESEARCHER spotlight

Two mutations in RNA splicing factors from the same cell confirmed with single-cell DNA-Seq

Justin Taylor, MD

University of Miami

RESEARCHER spotlight

Using CRISPR to understand different combinations of gene alterations

John Lee, MD, PhD

Fred Hutch

RESEARCHER spotlight

Single-cell analysis reveals extensive proteogenomic decoupling in leukemia

Adam Abate, PhD; Ben Demaree; Cyrille Delley

UCSF

Enhance the clinical evaluation of AML MRD by uncovering clonality

SHARE THIS PAGE